- Home
- DRUG vs TIL Comparison
DRUG vs TIL Comparison
Compare DRUG & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRUG
- TIL
- Stock Information
- Founded
- DRUG 2019
- TIL 2018
- Country
- DRUG United States
- TIL United States
- Employees
- DRUG N/A
- TIL N/A
- Industry
- DRUG Pharmaceuticals and Biotechnology
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- DRUG Health Care
- TIL Health Care
- Exchange
- DRUG Nasdaq
- TIL Nasdaq
- Market Cap
- DRUG 199.7M
- TIL 177.1M
- IPO Year
- DRUG N/A
- TIL 2021
- Fundamental
- Price
- DRUG $43.96
- TIL $26.99
- Analyst Decision
- DRUG Strong Buy
- TIL Buy
- Analyst Count
- DRUG 8
- TIL 6
- Target Price
- DRUG $83.60
- TIL $120.50
- AVG Volume (30 Days)
- DRUG 53.0K
- TIL 145.0K
- Earning Date
- DRUG 08-11-2025
- TIL 08-13-2025
- Dividend Yield
- DRUG N/A
- TIL N/A
- EPS Growth
- DRUG N/A
- TIL N/A
- EPS
- DRUG N/A
- TIL N/A
- Revenue
- DRUG N/A
- TIL N/A
- Revenue This Year
- DRUG N/A
- TIL N/A
- Revenue Next Year
- DRUG N/A
- TIL N/A
- P/E Ratio
- DRUG N/A
- TIL N/A
- Revenue Growth
- DRUG N/A
- TIL N/A
- 52 Week Low
- DRUG $0.94
- TIL $10.80
- 52 Week High
- DRUG $79.02
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- DRUG 69.20
- TIL 50.40
- Support Level
- DRUG $34.19
- TIL $23.82
- Resistance Level
- DRUG $46.13
- TIL $30.19
- Average True Range (ATR)
- DRUG 3.38
- TIL 2.34
- MACD
- DRUG 0.26
- TIL -0.10
- Stochastic Oscillator
- DRUG 82.17
- TIL 49.76
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.